Data on hyper-activation of GPVI signalling in obese patients: Towards the identification of novel antiplatelet targets in obesity.


Journal

Data in brief
ISSN: 2352-3409
Titre abrégé: Data Brief
Pays: Netherlands
ID NLM: 101654995

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 07 02 2019
accepted: 15 02 2019
entrez: 3 8 2019
pubmed: 3 8 2019
medline: 3 8 2019
Statut: epublish

Résumé

This data article is associated with the manuscript "GPVI surface expression and signalling pathway activation are increased in platelets from obese patients: elucidating potential anti-atherothrombotic targets in obesity" [1]. The study refers to a combination of different approaches in order to identify platelet-derived biomarkers in obesity. A total of 34 obese patients and their lean-matched controls were included in the study. We carried out a proteomic and functional (aggregation assays) analysis to find alterations in platelet-derived signalling pathways. After that, biochemical and mechanistic (flow cytometry assays) approaches were done in order to confirm a hyperactivation of the GPVI-related signalling pathway.

Identifiants

pubmed: 31372431
doi: 10.1016/j.dib.2019.103784
pii: S2352-3409(19)30135-0
pii: 103784
pmc: PMC6661234
doi:

Types de publication

Journal Article

Langues

eng

Pagination

103784

Subventions

Organisme : British Heart Foundation
ID : PG/18/36/33811
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/15/4/31268
Pays : United Kingdom
Organisme : British Heart Foundation
ID : SP/13/7/30575
Pays : United Kingdom

Références

Blood. 2004 Mar 15;103(6):2088-95
pubmed: 14645010
Methods Mol Med. 2007;139:339-53
pubmed: 18287684
Nucleic Acids Res. 2009 Jan;37(Database issue):D412-6
pubmed: 18940858
Atherosclerosis. 2019 Feb;281:62-70
pubmed: 30658193
Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14440-5
pubmed: 8962070

Auteurs

María N Barrachina (MN)

Platelet Proteomics Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade Santiago de Compostela, Spain.
Instituto de Investigación Sanitaria de Santiago (IDIS), Spain.

Irene Izquierdo (I)

Platelet Proteomics Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade Santiago de Compostela, Spain.
Instituto de Investigación Sanitaria de Santiago (IDIS), Spain.

Lidia Hermida-Nogueira (L)

Platelet Proteomics Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade Santiago de Compostela, Spain.
Instituto de Investigación Sanitaria de Santiago (IDIS), Spain.

Aurelio M Sueiro (AM)

Grupo de Endocrinología Molecular y Celular, Instituto de Investigación Sanitaria de Santiago (IDIS)/ Servicio de Endocrinología, Xerencia de Xestión Integrada de Santiago (XXS), Spain.

Esteban Guitián (E)

Mass Spectrometry and Proteomic Unit, Rede de Infraestructuras de Apoio á Investigación e ao Desenvolvemento Tecnolóxico, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.

Felipe F Casanueva (FF)

Instituto de Investigación Sanitaria de Santiago (IDIS), Spain.
Grupo de Endocrinología Molecular y Celular, Instituto de Investigación Sanitaria de Santiago (IDIS)/ Servicio de Endocrinología, Xerencia de Xestión Integrada de Santiago (XXS), Spain.

Richard W Farndale (RW)

Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QW, United Kingdom.

Masaaki Moroi (M)

Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QW, United Kingdom.

Stephanie M Jung (SM)

Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QW, United Kingdom.

María Pardo (M)

Instituto de Investigación Sanitaria de Santiago (IDIS), Spain.
Grupo Obesidómica - Instituto de Investigación Sanitaria de Santiago (IDIS).

Ángel García (Á)

Platelet Proteomics Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade Santiago de Compostela, Spain.
Instituto de Investigación Sanitaria de Santiago (IDIS), Spain.

Classifications MeSH